2024’s Mid-Year Review: FDA-Approved Cardiorenal Metabolic Drugs and DevicesÂ
The first half of 2024 ushered in a wave of transformative FDA approvals in cardiorenal metabolic health. Get up to date now!
2022 FDA-Approved Cardiometabolic Drugs and Devices
Although the U.S. Food and Drug Administration (FDA) approved a record-low number of drugs and devices from January through September 2022, many of those were in the realm of cardiorenal metabolic health. January 2022 Daridorexant. In the first major move of 2022, the FDA approved daridorexant for the treatment of adults with insomnia on Jan. […]
